We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 4

1.
FIG. 2.

FIG. 2. From: Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy.

Vaccination boosted binding antibody responses to HIV-1 antigens. The levels of anti-gp120 (circles) and anti-p24 (squares) antibodies in plasma were quantified using a standard ELISA and are expressed as a midpoint antibody titer.

Xia Jin, et al. J Virol. 2002 March;76(5):2206-2216.
2.
FIG. 1.

FIG. 1. From: Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy.

Virological and immunological changes observed during vaccination. The plasma HIV-1 RNA levels (circles) and CD4 counts (triangles) of each patient were assessed longitudinally. Each panel represents results for one patient, and the arrows indicate days of vaccination.

Xia Jin, et al. J Virol. 2002 March;76(5):2206-2216.
3.
FIG. 3.

FIG. 3. From: Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy.

Transient elevation of T helper cell responses was achieved by vaccination. T-cell proliferative responses to HIV-1 gp160 (circles) and p24 (squares) were measured using freshly isolated PBMC from each patient. The results are expressed as stimulation indexes, where control antigen stimulation was given a value of 1.

Xia Jin, et al. J Virol. 2002 March;76(5):2206-2216.
4.
FIG.4.

FIG.4. From: Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy.

(a) Precise quantitation of HIV-specific CD8+ T-cell responses using the intracellular cytokine staining assay. PBMC from one HIV-infected individual were stimulated by vaccinia virus expression negative control Eco, HIV antigens (Env, Gag, Pol, and Nef) and positive control SEB first, following by staining with anti-CD3, -CD4, -CD8 and -IFN-γ antibodies. The percentages of antigen-specific CD8+ T cells were enumerated and are expressed as a percentage on the upper right quadrant of each plot. (b) Persistent increase in HIV-1-specific CD8+ T cells during vaccination. Longitudinal PBMC samples from each vaccine recipient were used for assessing HIV-1 or control antigen-specific CD8+ T-cell responses. The results were summarized as the percentage of IFN-γ-producing CD8+ T cells to Env (circles), Gag (squares), Pol (triangles), and Pol/Nef (diamonds) after the value for background Eco (inverted diamonds) was subtracted.

Xia Jin, et al. J Virol. 2002 March;76(5):2206-2216.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk